相关实验视频

Updated: Jan 17, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

在阿尔茨海默氏病中,阿波利波蛋白E和Tau的相互作用

Subashchandrabose Chinnathambi¹, Anusree Adityan¹, Hariharakrishnan Chidambaram¹

¹Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India.

Advances in protein chemistry and structural biology

|September 19, 2025

概括

陶蛋白聚合成神经纤维状结是由与膜脂质和Apo E4等蛋白质的相互作用影响的. 这些相互作用是理解神经退行性疾病 (如阿尔茨海默氏症) 的关键.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
细胞生物学细胞生物学

背景情况:

蛋白对于微管稳定和细胞功能至关重要.
病理性tau修饰导致聚合到神经纤维状结 (NFTs).
与脂质和蛋白质的相互作用与神经退行性疾病有关.

研究的目的:

调查膜脂质和蛋白质相互作用在Tau聚合中的作用.
了解这些相互作用如何导致Tau病理和神经毒性.

主要方法:

对与脂 (DOPC,DPPC) 和蛋白质 (Apo E4) 的相互作用进行分析.
研究脂酶C (PLC) 和DEPC对Tau聚合的影响.
检查膜脂质组成对陶纤维化的影响.

主要成果:

特定的脂和Apo E4显著调节结构和聚合动力学.
PLC和DEPC通过不同的机制影响tau聚合.
改变的膜性质会影响陶膜相互作用,促进纤维化.

结论:

膜脂质和蛋白质相互作用是阿尔茨海默病和tau病变中的tau病理的关键驱动因素.
了解这些相互作用为神经退行性疾病提供了潜在的治疗点.
脂质稳定和膜完整性对于预防与相关的神经毒性至关重要.

关键词:

粉样蛋白-β 是一种蛋白质.胆固醇胆固醇胆固醇脂质双层膜是什么意思膜流动性膜流动性神经纤维状的纠.的聚合是tau的聚合.

更多相关视频

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...